<p>Ameritas Advisory Services LLC 在第四季度收购了 Exelixis, Inc.（NASDAQ:EXEL - 免费报告）股票的新头寸，根据其最近向证券交易委员会的披露，该基金收购了 34,270 股生物技术公司的股票，价值约为 1,502,000 美元。</p>
<ul>
<li>Exelixis 报告稳健的收益——新高是否重回视野？</li>
</ul>
<p>其他一些对冲基金最近也买卖了该公司的股票。Farallon Capital Management LLC 在第三季度将其在 Exelixis 的持仓提高了 21.6%。Farallon Capital Management LLC 目前拥有 19,501,500 股生物技术公司的股票，价值 805,412,000 美元，在上个季度又购买了 3,466,000 股。Assetmark Inc. 在第三季度将其在 Exelixis 的持仓提高了 1,230.8%。Assetmark Inc. 目前拥有 3,195,971 股生物技术公司的股票，价值 131,994,000 美元，在上个季度又购买了 2,955,813 股。AQR Capital Management LLC 在第三季度将其在 Exelixis 的持仓提高了 20.7%。AQR Capital Management LLC 目前拥有 9,181,359 股生物技术公司的股票，价值 379,190,000 美元，在上个季度又购买了 1,575,280 股。Allianz Asset Management GmbH 在第三季度将其在 Exelixis 的持仓提高了 153.3%。Allianz Asset Management GmbH 目前拥有 2,462,948 股生物技术公司的股票，价值 101,720,000 美元，在上个季度又购买了 1,490,520 股。最后，瑞银集团（UBS Group AG）在第三季度将其在 Exelixis 的持仓提高了 100.1%。瑞银集团目前拥有 2,655,069 股生物技术公司的股票，价值 109,654,000 美元，在上个季度又购买了 1,328,087 股。85.27% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Exelixis 价格表现</h2>
<p>EXEL 股票在周五开盘价为 51.10 美元。Exelixis, Inc. 的 1 年低点为 33.76 美元，1 年高点为 51.63 美元。该公司的市值为 128.4 亿美元，市盈率为 16.98，PEG 比率为 1.08，贝塔值为 0.38。该公司的 50 日简单移动平均线为 44.13 美元，200 日简单移动平均线为 43.44 美元。</p>
<ul>
<li>3 只适合软着陆的股票，如果真的有的话</li>
</ul>
<p>Exelixis（NASDAQ:EXEL - 获取免费报告）最近在 5 月 5 日星期二发布了其收益结果。该生物技术公司报告季度每股收益为 0.87 美元，超出分析师共识预期的 0.75 美元，超出 0.12 美元。该公司在本季度的收入为 6.1081 亿美元，而共识预期为 6.0751 亿美元。Exelixis 的股本回报率为 39.89%，净利润率为 35.08%。该公司的季度收入较去年同期增长了 10.0%。在去年同期，该公司每股收益为 0.55 美元。卖方分析师预计 Exelixis, Inc. 在当前财政年度将发布 3.15 美元的每股收益。</p>
<h2>内部活动</h2>
<p>在相关消息中，执行副总裁 Patrick J. Haley 于 2 月 17 日星期二出售了 67,814 股该股票。股票以平均价格 43.52 美元出售，总交易额为 2,951,265.28 美元。出售后，该执行副总裁在公司中持有 381,908 股，价值约为 16,620,636.16 美元。这代表其持仓减少了 15.08%。该交易在向 SEC 的文件中披露，可以通过此超链接访问。此外，首席财务官 Christopher J. Senner 于 2 月 17 日星期二出售了 30,617 股该股票。股票以平均价格 43.67 美元出售，总价值为 1,337,044.39 美元。出售后，首席财务官在公司中持有 976,092 股，价值 42,625,937.64 美元。该交易使其持仓减少了 3.04%。该出售的披露信息可在 SEC 文件中找到。在过去的九十天里，内部人士出售了价值 17,014,813 美元的 382,811 股公司股票。2.60% 的股票由公司内部人士持有。</p>
<h2>华尔街分析师观点</h2>
<ul>
<li>3 只强劲的生物技术表现者，值得关注，随着行业接近突破</li>
</ul>
<p>一些股票分析师对该公司发表了看法。加拿大皇家银行在 3 月 2 日星期一的研究报告中将 Exelixis 的目标价格从 46.00 美元下调至 43.00 美元，并对该公司设定了 “行业表现” 评级。摩根士丹利在 5 月 6 日星期三的研究报告中将 Exelixis 的目标价格从 49.00 美元上调至 50.00 美元，并给予该股票 “等权重” 评级。Stifel Nicolaus 在 5 月 6 日星期三的研究报告中将 Exelixis 的目标价格从 44.00 美元上调至 47.00 美元，并给予该公司 “持有” 评级。TD Cowen 在 5 月 6 日星期三的研究报告中将 Exelixis 的目标价格从 51.00 美元上调至 55.00 美元，并给予该公司 “买入” 评级。最后，Truist Financial 在 4 月 27 日星期一的研究报告中将 Exelixis 升级为 “强烈买入” 评级。一位分析师对该股票给予了强烈买入评级，九位给予了买入评级，十一位给予了持有评级，两位给予了卖出评级。根据 MarketBeat，该股票目前的平均评级为 “持有”，平均目标价格为 47.35 美元。</p>
<p><strong>获取我们关于 Exelixis 的最新研究报告</strong></p>
<h2>Exelixis 公司简介</h2>
<p>（免费报告）</p>
<p>Exelixis, Inc. 是一家生物技术公司，专注于小分子疗法的发现、开发和商业化，主要用于癌症治疗。该公司基于利用模式生物遗传学和高通量筛选的平台，专注于研究调节肿瘤生长和转移相关的关键信号通路的激酶抑制剂。Exelixis 的转化研究方法旨在将新化合物从早期发现推进到临床开发和监管批准。</p>
<p>该公司最知名的产品包括 CABOMETYX®（cabozantinib），已获批准用于治疗晚期肾细胞癌和肝细胞癌，以及 COMETRIQ®（cabozantinib），用于治疗转移性髓样甲状腺癌。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们认为比 Exelixis 更好的股票</li>
<li>YETI 在财报超预期和上调前景后反弹</li>
<li>三家领先量子公司的第一季度财报对比</li>
<li>思科的垂直反弹可能仍处于早期阶段</li>
<li>亚马逊与阿里巴巴：目前显然更具价值的选择</li>
</ul>
<p><strong>想看看其他对 EXEL 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com，获取 Exelixis, Inc.（NASDAQ:EXEL - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVhFTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVhFTA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Exelixis 吗？</h2>
<p>在考虑 Exelixis 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 Exelixis 并不在名单上。</p>
<p>虽然 Exelixis 目前在分析师中被评为持有，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

伊克力西斯

2 倍做多纳斯达克生物技术 ETF - ProShares

动态生物技术与基因组 ETF - Invesco

<p>Ameritas Advisory Services LLC 在第四季度收购了 34,270 股 Exelixis, Inc.（纳斯达克代码：EXEL），价值约 150 万美元。其他对冲基金也增加了在该公司的持仓。Exelixis 报告了稳健的财报，季度收入为 6.1081 亿美元，每股收益为 0.87 美元，超出预期。分析师对该股票的评级和目标价格不一，反映出对其表现的不同看法</p>

<p>Ameritas Advisory Services LLC acquired a new position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 34,270 shares of the biotechnology company's stock, valued at approximately $1,502,000.</p>
<div class="lb-trans"><p>Ameritas Advisory Services LLC 在第四季度收购了 Exelixis, Inc.（NASDAQ:EXEL - 免费报告）股票的新头寸，根据其最近向证券交易委员会的披露，该基金收购了 34,270 股生物技术公司的股票，价值约为 1,502,000 美元。</p>
</div><ul>
<li>Exelixis Reports Solid Earnings—Are New Highs Back on the Table?</li>
</ul>
<div class="lb-trans"><ul>
<li>Exelixis 报告稳健的收益——新高是否重回视野？</li>
</ul>
</div><p>A number of other hedge funds have also recently bought and sold shares of the company. Farallon Capital Management LLC raised its position in Exelixis by 21.6% in the 3rd quarter. Farallon Capital Management LLC now owns 19,501,500 shares of the biotechnology company's stock worth $805,412,000 after buying an additional 3,466,000 shares during the last quarter. Assetmark Inc. raised its position in Exelixis by 1,230.8% in the 3rd quarter. Assetmark Inc. now owns 3,195,971 shares of the biotechnology company's stock worth $131,994,000 after buying an additional 2,955,813 shares during the last quarter. AQR Capital Management LLC raised its position in Exelixis by 20.7% in the 3rd quarter. AQR Capital Management LLC now owns 9,181,359 shares of the biotechnology company's stock worth $379,190,000 after buying an additional 1,575,280 shares during the last quarter. Allianz Asset Management GmbH raised its position in Exelixis by 153.3% in the 3rd quarter. Allianz Asset Management GmbH now owns 2,462,948 shares of the biotechnology company's stock worth $101,720,000 after buying an additional 1,490,520 shares during the last quarter. Finally, UBS Group AG raised its position in Exelixis by 100.1% in the 3rd quarter. UBS Group AG now owns 2,655,069 shares of the biotechnology company's stock worth $109,654,000 after buying an additional 1,328,087 shares during the last quarter. 85.27% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他一些对冲基金最近也买卖了该公司的股票。Farallon Capital Management LLC 在第三季度将其在 Exelixis 的持仓提高了 21.6%。Farallon Capital Management LLC 目前拥有 19,501,500 股生物技术公司的股票，价值 805,412,000 美元，在上个季度又购买了 3,466,000 股。Assetmark Inc. 在第三季度将其在 Exelixis 的持仓提高了 1,230.8%。Assetmark Inc. 目前拥有 3,195,971 股生物技术公司的股票，价值 131,994,000 美元，在上个季度又购买了 2,955,813 股。AQR Capital Management LLC 在第三季度将其在 Exelixis 的持仓提高了 20.7%。AQR Capital Management LLC 目前拥有 9,181,359 股生物技术公司的股票，价值 379,190,000 美元，在上个季度又购买了 1,575,280 股。Allianz Asset Management GmbH 在第三季度将其在 Exelixis 的持仓提高了 153.3%。Allianz Asset Management GmbH 目前拥有 2,462,948 股生物技术公司的股票，价值 101,720,000 美元，在上个季度又购买了 1,490,520 股。最后，瑞银集团（UBS Group AG）在第三季度将其在 Exelixis 的持仓提高了 100.1%。瑞银集团目前拥有 2,655,069 股生物技术公司的股票，价值 109,654,000 美元，在上个季度又购买了 1,328,087 股。85.27% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Exelixis Price Performance</h2>
<div class="lb-trans"><h2>Exelixis 价格表现</h2>
</div><p>EXEL stock opened at $51.10 on Friday. Exelixis, Inc. has a 1-year low of $33.76 and a 1-year high of $51.63. The company has a market capitalization of $12.84 billion, a price-to-earnings ratio of 16.98, a PEG ratio of 1.08 and a beta of 0.38. The business has a 50 day simple moving average of $44.13 and a two-hundred day simple moving average of $43.44.</p>
<div class="lb-trans"><p>EXEL 股票在周五开盘价为 51.10 美元。Exelixis, Inc. 的 1 年低点为 33.76 美元，1 年高点为 51.63 美元。该公司的市值为 128.4 亿美元，市盈率为 16.98，PEG 比率为 1.08，贝塔值为 0.38。该公司的 50 日简单移动平均线为 44.13 美元，200 日简单移动平均线为 43.44 美元。</p>
</div><ul>
<li>3 Stocks to Buy for a Soft Landing, If There Is One</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只适合软着陆的股票，如果真的有的话</li>
</ul>
</div><p>Exelixis (NASDAQ:EXEL - Get Free Report) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 EPS for the quarter, beating analysts' consensus estimates of $0.75 by $0.12. The firm had revenue of $610.81 million during the quarter, compared to the consensus estimate of $607.51 million. Exelixis had a return on equity of 39.89% and a net margin of 35.08%.The company's quarterly revenue was up 10.0% compared to the same quarter last year. During the same period in the prior year, the company earned $0.55 EPS. Sell-side analysts anticipate that Exelixis, Inc. will post 3.15 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Exelixis（NASDAQ:EXEL - 获取免费报告）最近在 5 月 5 日星期二发布了其收益结果。该生物技术公司报告季度每股收益为 0.87 美元，超出分析师共识预期的 0.75 美元，超出 0.12 美元。该公司在本季度的收入为 6.1081 亿美元，而共识预期为 6.0751 亿美元。Exelixis 的股本回报率为 39.89%，净利润率为 35.08%。该公司的季度收入较去年同期增长了 10.0%。在去年同期，该公司每股收益为 0.55 美元。卖方分析师预计 Exelixis, Inc. 在当前财政年度将发布 3.15 美元的每股收益。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In related news, EVP Patrick J. Haley sold 67,814 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $43.52, for a total transaction of $2,951,265.28. Following the sale, the executive vice president owned 381,908 shares in the company, valued at approximately $16,620,636.16. This represents a 15.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Christopher J. Senner sold 30,617 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $43.67, for a total value of $1,337,044.39. Following the sale, the chief financial officer owned 976,092 shares in the company, valued at $42,625,937.64. The trade was a 3.04% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 382,811 shares of company stock worth $17,014,813. 2.60% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在相关消息中，执行副总裁 Patrick J. Haley 于 2 月 17 日星期二出售了 67,814 股该股票。股票以平均价格 43.52 美元出售，总交易额为 2,951,265.28 美元。出售后，该执行副总裁在公司中持有 381,908 股，价值约为 16,620,636.16 美元。这代表其持仓减少了 15.08%。该交易在向 SEC 的文件中披露，可以通过此超链接访问。此外，首席财务官 Christopher J. Senner 于 2 月 17 日星期二出售了 30,617 股该股票。股票以平均价格 43.67 美元出售，总价值为 1,337,044.39 美元。出售后，首席财务官在公司中持有 976,092 股，价值 42,625,937.64 美元。该交易使其持仓减少了 3.04%。该出售的披露信息可在 SEC 文件中找到。在过去的九十天里，内部人士出售了价值 17,014,813 美元的 382,811 股公司股票。2.60% 的股票由公司内部人士持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><ul>
<li>3 Strong Biotech Performers To Watch As Sector Nears Breakout</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只强劲的生物技术表现者，值得关注，随着行业接近突破</li>
</ul>
</div><p>A number of equities analysts have weighed in on the company. Royal Bank Of Canada decreased their target price on Exelixis from $46.00 to $43.00 and set a &#34;sector perform&#34; rating for the company in a research report on Monday, March 2nd. Morgan Stanley boosted their target price on Exelixis from $49.00 to $50.00 and gave the stock an &#34;equal weight&#34; rating in a research report on Wednesday, May 6th. Stifel Nicolaus boosted their price target on Exelixis from $44.00 to $47.00 and gave the company a &#34;hold&#34; rating in a research note on Wednesday, May 6th. TD Cowen boosted their price target on Exelixis from $51.00 to $55.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, May 6th. Finally, Truist Financial upgraded Exelixis to a &#34;strong-buy&#34; rating in a research note on Monday, April 27th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of &#34;Hold&#34; and an average price target of $47.35.</p>
<div class="lb-trans"><p>一些股票分析师对该公司发表了看法。加拿大皇家银行在 3 月 2 日星期一的研究报告中将 Exelixis 的目标价格从 46.00 美元下调至 43.00 美元，并对该公司设定了 “行业表现” 评级。摩根士丹利在 5 月 6 日星期三的研究报告中将 Exelixis 的目标价格从 49.00 美元上调至 50.00 美元，并给予该股票 “等权重” 评级。Stifel Nicolaus 在 5 月 6 日星期三的研究报告中将 Exelixis 的目标价格从 44.00 美元上调至 47.00 美元，并给予该公司 “持有” 评级。TD Cowen 在 5 月 6 日星期三的研究报告中将 Exelixis 的目标价格从 51.00 美元上调至 55.00 美元，并给予该公司 “买入” 评级。最后，Truist Financial 在 4 月 27 日星期一的研究报告中将 Exelixis 升级为 “强烈买入” 评级。一位分析师对该股票给予了强烈买入评级，九位给予了买入评级，十一位给予了持有评级，两位给予了卖出评级。根据 MarketBeat，该股票目前的平均评级为 “持有”，平均目标价格为 47.35 美元。</p>
</div><p><strong>Get Our Latest Research Report on Exelixis</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Exelixis 的最新研究报告</strong></p>
</div><h2>Exelixis Profile</h2>
<div class="lb-trans"><h2>Exelixis 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis's translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.</p>
<div class="lb-trans"><p>Exelixis, Inc. 是一家生物技术公司，专注于小分子疗法的发现、开发和商业化，主要用于癌症治疗。该公司基于利用模式生物遗传学和高通量筛选的平台，专注于研究调节肿瘤生长和转移相关的关键信号通路的激酶抑制剂。Exelixis 的转化研究方法旨在将新化合物从早期发现推进到临床开发和监管批准。</p>
</div><p>The company's most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.</p>
<div class="lb-trans"><p>该公司最知名的产品包括 CABOMETYX®（cabozantinib），已获批准用于治疗晚期肾细胞癌和肝细胞癌，以及 COMETRIQ®（cabozantinib），用于治疗转移性髓样甲状腺癌。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Exelixis</li>
<li>YETI Rallies After Earnings Beat and Raised Outlook</li>
<li>How the 3 Leading Quantum Firms Stack Up After Q1 Earnings</li>
<li>Cisco’s Vertical Rally May Still Be in the Early Innings</li>
<li>Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Exelixis 更好的股票</li>
<li>YETI 在财报超预期和上调前景后反弹</li>
<li>三家领先量子公司的第一季度财报对比</li>
<li>思科的垂直反弹可能仍处于早期阶段</li>
<li>亚马逊与阿里巴巴：目前显然更具价值的选择</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding EXEL?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 EXEL 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com，获取 Exelixis, Inc.（NASDAQ:EXEL - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVhFTA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=EXEL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Exelixis Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Exelixis 吗？</h2>
</div><p>Before you consider Exelixis, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Exelixis 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exelixis wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 Exelixis 并不在名单上。</p>
</div><p>While Exelixis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Exelixis 目前在分析师中被评为持有，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Ameritas Advisory Services LLC Purchases Shares of 34,270 Exelixis, Inc. $EXEL

Market Beat

医疗业 ETF - SPDR

医疗业 ETF - Vanguard

基因改革 ETF - ARK

纽交所高增长板生物技术指数 ETF - First Trust

纳斯达克生物科技指数 ETF - iShares Nasdaq

医药突破 ETF - ALPS

标普生物技术 ETF - SPDR

标普生物技术 3 倍做多 - Direxion

生物科技 ETF - VanEck Vectors

美国制药 ETF - iShares

安联集团(ADR)

安联保险集团

瑞银集团

加拿大皇家银行

摩根士丹利

Stifel Financial

Toronto Dominion Bank

Truist Financial

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

Ameritas Advisory Services LLC 购入了 34,270 股 Exelixis, Inc. $EXEL 的股票